NASDAQ:FMI

Foundation Medicine (FMI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$137.00
$137.00
50-Day Range
N/A
52-Week Range
$31.70
$137.20
Volume
N/A
Average Volume
621,352 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FMI stock logo

About Foundation Medicine Stock (NASDAQ:FMI)

Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.

FMI Stock News Headlines

The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Medicine: It Works
The system that called 2023’s top 7 stocks is at it again…
Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.
Winter Park Health Foundation CEO to retire
Whole Exome Sequencing Global Market Report 2023
See More Headlines
Receive FMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foundation Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2018
Today
4/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:FMI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Troy Cox (Age 54)
    CEO, Pres & Director
  • Mr. Michael Doherty (Age 59)
    Head of Product Devel.
  • Mr. Jason Ryan (Age 44)
    Chief Financial Officer
  • Mr. Konstantin Fiedler (Age 52)
    Chief Operating Officer
  • Mr. Tom Godden
    Chief Information Officer

FMI Stock Analysis - Frequently Asked Questions

How were Foundation Medicine's earnings last quarter?

Foundation Medicine, Inc. (NASDAQ:FMI) issued its quarterly earnings results on Wednesday, May, 2nd. The company reported ($1.02) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.08. The company earned $52.84 million during the quarter, compared to analysts' expectations of $44.99 million. Foundation Medicine's quarterly revenue was up 100.7% compared to the same quarter last year. During the same period last year, the firm posted ($1.31) earnings per share.

What other stocks do shareholders of Foundation Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Foundation Medicine investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Gilead Sciences (GILD), HP (HPQ), Inovio Pharmaceuticals (INO), Viveve Medical (VIVE), Exact Sciences (EXAS), GW Pharmaceuticals (GWPH), NVIDIA (NVDA) and QUALCOMM (QCOM).

This page (NASDAQ:FMI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners